{
    "organizations": [],
    "uuid": "46ca9e3b604d07014e31507deca1cbc12354bb50",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-tetra-bio-pharma-receives-approval/brief-tetra-bio-pharma-receives-approval-from-health-canada-of-its-phase-1-clinical-trial-with-ppp005-idUSASB0C11C",
    "ord_in_thread": 0,
    "title": "BRIEF-Tetra Bio-Pharma Receives Approval From Health Canada Of Its Phase 1 Clinical Trial With PPP005 (Cannabis Oil)",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - Tetra Bio Pharma Inc:\n* TETRA BIO-PHARMA RECEIVES APPROVAL FROM HEALTH CANADA OF ITS PHASE 1 CLINICAL TRIAL WITH PPP005 (CANNABIS OIL)\n* TETRA BIO PHARMA - RECEIVED NO OBJECTION LETTER FROM THERAPEUTIC PRODUCTS DIRECTORATE HEALTH CANADA OF ITS PHASE 1 CLINICAL TRIAL WITH PPP005 (CANNABIS OIL) Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-16T21:09:00.000+02:00",
    "crawled": "2018-01-17T19:46:20.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "tetra",
        "bio",
        "pharma",
        "inc",
        "tetra",
        "receives",
        "approval",
        "health",
        "canada",
        "phase",
        "clinical",
        "trial",
        "ppp005",
        "cannabis",
        "oil",
        "tetra",
        "bio",
        "pharma",
        "received",
        "objection",
        "letter",
        "therapeutic",
        "product",
        "directorate",
        "health",
        "canada",
        "phase",
        "clinical",
        "trial",
        "ppp005",
        "cannabis",
        "oil",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}